<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03442153</url>
  </required_header>
  <id_info>
    <org_study_id>Ambrosia</org_study_id>
    <nct_id>NCT03442153</nct_id>
  </id_info>
  <brief_title>Comparative Efficacy and Tolerability of No7 in Osteoarthritis of the Knee</brief_title>
  <official_title>Comparative Efficacy and Tolerability of No7 in Osteoarthritis of the Knee: A Double Blind, Randomized, Placebo Controlled Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ambrosia - SupHerb Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ambrosia - SupHerb Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of dietary supplement Solgar No7 in 76 adult Osteoarthritis
      of the Knee Patients, while the other half will receive placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Solgar No7 is a Dietary Supplement marketed in Israel on a regular basis with the approval of
      the Israeli Ministry of Health. The product is based on Herbal Extracts and Vitamins. The
      individual components of the product were effective in some studies in relieving pain and
      inflammation in such patients. This Study evaluates the effect of these components as a
      complex.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The product in not drug or medical device (but a dietary supplement). There are 76 participants divided inti 2 groups : experimental group (38) and Placebo group (38). The period of the intervention: 90 days</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Intensity</measure>
    <time_frame>Pain intensity Reported to the Doctor after one month of the treatment. Each item is scored 0-10 (0=no pain; 10=pain as bad as can be), yielding a total between 0 and 30.</time_frame>
    <description>Self reported pain intensity in the scale 1-10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Knee Stiffness</measure>
    <time_frame>nee Stiffness checked by the Doctor after one month of treatment. Each item is scored 0-10 (0=no pain; 10=pain as bad as can be), yielding a total between 0 and 30</time_frame>
    <description>The stiffness of the knee according to the doctor evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non Steroidal Anti Inflammatory Drugs Usage</measure>
    <time_frame>Pain Medication Usage as Reported to the Doctor after one month of treatment. Each item is scored as a number of the dose units that were used during the all period (0=no medications, 1=only one dose of medication etc)</time_frame>
    <description>Self reported Non Steroidal Anti Inflammatory Drugs Usage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Reactions</measure>
    <time_frame>Adverse Reactions as Reported to the Doctor over the period of the treatment. Each item is scored as a number of the dose units that were used during the all period (0=no adverse reactions, 1=only one adverse reaction etc)</time_frame>
    <description>Self reported Adverse Reactions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Solgar No7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aflapin 100 mg and Collagen UC2 40 mg by mouth every 24 hours for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for Solgar No7</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 Capsule by mouth, every 24 hours for 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Solgar No7 Complex</intervention_name>
    <description>Solgar No7 Capsules</description>
    <arm_group_label>Solgar No7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo tablets Cellulose</description>
    <arm_group_label>Placebo for Solgar No7</arm_group_label>
    <other_name>Placebo for Solgar No7</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Osteoarthritis (at least 2-nd grade according to Kellgren Classification)

          -  Ability to walk independently

          -  Pain Intensity of 4 or more according to Visual Analogue Scale

          -  NSAIDs usage of 5 times or more per month during 3 months before the intervention

          -  Ability to understand the benefits and risks of the proposed treatment and can provide
             answers to the required questions and fill out a questionnaire in Hebrew

          -  Early consent of participants not to start a new treatment for Osteoarthritis
             including medication, surgery, physiotherapy, laser therapy, etc. during the period of
             the study (3 months) - except for a clear medical need (should report to the
             investigators immediately)

        Exclusion Criteria:

          -  Inflammatory Arthropathy, Severe Rheumatoid Arthritis, Psoriatic Arthritis or Gout

          -  History of injection of pharmacological material (steroids, anesthetic, hyaluronic
             acid or any other pharmacological substance) into the knee joint during the six months
             prior to the start of the study

          -  Taking of biological drugs that may affect inflammatory conditions (such as anti-TNF-
             alpha, etc.) or oral PO steroids - even if given to another disease, for more than 5
             days during 3 months prior to the start of the study

          -  Chronic administration of any anti-inflammatory drug during the study period and / or
             at least one month prior to commencement of the study.

          -  Chronic administration of medical cannabis

          -  Use of analgetics in a formulation that provides a half-life of over 24 hours (eg,
             Butrans, Fentanyl)

          -  Chronic use of vitamin K antagonists, Heparin, Enoxaparin

          -  Injury to the knee during six months prior to the experiment

          -  Expectations of surgical intervention, physiotherapy or other treatment of
             osteoarthritis before the end of the study period

          -  Significant irregularities in renal or liver function, active malignant disease in the
             last 3 years, heart failure, uncontrolled hypertension, active peptic ulcer,
             hematologic diseases, severe neurological diseases, and mental illness with seizures
             in the last two years.

          -  Peripheral neuropathy that treated by any drug

          -  High alcohol consumption (over 2 standard doses per day)

          -  Sensitivity to one of the ingredients and / or sensitivity to NSAIDs. It is Possible
             to include a patient who is sensitive to a specific drug from the family of NSAIDs,
             but can take other drugs from this family.

          -  Any medical condition or treatment which, in the opinion of the investigators, may
             mask the results of the study and / or interfere with the research questions and / or
             terminate the research properly and / or endanger the participant in any way during
             the course of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guy Rubin</last_name>
    <role>Principal Investigator</role>
    <affiliation>HaEmek Medical Center, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Evgeny Vaysberg, Pharmacist</last_name>
    <phone>+972506670597</phone>
    <email>evgenyiw@solgar.co.il</email>
  </overall_contact>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2018</study_first_submitted>
  <study_first_submitted_qc>February 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2018</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

